KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.15
-0.64 (-0.32%)
AAPL  258.73
+2.95 (1.15%)
AMD  197.19
-10.12 (-4.88%)
BAC  53.30
+0.75 (1.42%)
GOOG  298.33
-7.69 (-2.51%)
META  631.00
-8.77 (-1.37%)
MSFT  394.84
-6.48 (-1.61%)
NVDA  179.77
-3.04 (-1.66%)
ORCL  154.06
-6.08 (-3.80%)
TSLA  403.50
-13.94 (-3.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.